1. MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer
- Author
-
Wang C, Liu Y, Guo W, Zhu X, Ahuja N, and Fu T
- Subjects
colorectal cancer ,methylation ,MAPT ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Chuntao Wang,1 Yanliang Liu,1 Wenyi Guo,1 Xu Zhu,1 Nita Ahuja,2 Tao Fu11Department of Gastrointestinal Surgery II, Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital, Wuhan University, Wuhan, People’s Republic of China; 2Department of Surgery, Yale School of Medicine, New Haven, CT, USABackground: The methylation of microtubule-associated protein tau (MAPT) was first described in patients with Alzheimer’s disease. In this study, we aim to determine if MAPT promoter CpG island is hypermethylated and whether this signature could work as a prognostic marker for patients with stage II colorectal cancer (CRC).Methods: MAPT methylation level and CpG island methylator phenotype (CIMP) status were examined. The prognostic value of MAPT methylation was analyzed using Cox regression analysis.Results: Amongst stage II CRC patients (n=107), hypermethylation of MAPT promoter CpG island was seen in 23.4% of them. MAPT methylation was much more frequent in patients with age ≥60 compared to age
- Published
- 2019